Accessibility Menu
Endonovo Therapeutics logo

Endonovo Therapeutics(OTC) ENDV

Market Cap$180.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-100%
5 Year-100%
1 Year-50%
1 Month+0%
$0.00
+0.00%
+0.00Today
Endonovo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-03
Endonovo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9,900%USD 0.002026-07-24
1 month+0%USD 0.002026-07-02
3 month+0%USD 0.002026-05-05
Year to date+0%USD 0.002025-12-31
1 year-50%USD 0.002025-08-01
3 year-99.09%USD 0.012023-08-04
5 year-99.65%USD 0.032021-08-04
Since inception-100%USD 150.002013-02-20

Endonovo Therapeutics Financials at a Glance

Market Cap

$180.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.23M

EPS (TTM)

-$0.00

P/E Ratio

-0.07

Dividend

$0.00

Beta (Volatility)

-10.27 (Low)

Price

$0.00

Volume

999,999

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 25, 2026

ENDV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company focused on developing non-invasive electroceutical medical devices for regenerative medicine. The primary product, SofPulse, aims to provide therapeutic relief for various medical conditions, including chronic wounds and post-operative pain.

Products and Services
  • SofPulse: Advanced non-invasive therapeutic device
  • Applications for soft tissue injuries and chronic wounds
  • Technology for managing central nervous system disorders
Growth Outlook
  • Expanding applications in cardiovascular and kidney disorders
  • Potential market growth in regenerative medicine sector
  • Increased focus on non-invasive treatment options
Financial Highlights
  • Recent quarterly net income of -$586,475
  • Trailing twelve months (TTM) revenue of $0
  • Current liabilities significantly exceed total assets
Endonovo Therapeutics, Inc. operates in a niche market with a focus on innovative medical technology. The company's flagship product, SofPulse, is designed to address a variety of health issues, positioning it well within the growing field of regenerative medicine. Despite recent financial challenges, including a net income loss, the company is exploring avenues for growth, particularly in expanding its product applications. The current financial landscape indicates a need for strategic management of liabilities, as total liabilities significantly surpass total assets. Investors may find interest in the potential for future growth as the market for non-invasive medical treatments continues to evolve.
AI Generated • Jul 31, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Alan Brian Collier

Website

www.endonovo.com

Headquarters

Woodland Hills, CA 91367, US

ENDV Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

7.79%

Return on Capital

N/A

Return on Assets

-11338.08%

Earnings Yield

-14.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$180.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.81B

Volume

1000.00K

Avg. Volume

392.05K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$992.27K

EBITDA

-$992.27K

Operating Cash Flow

$35.16K

Capital Expenditure

$1.00

Free Cash Flow

$35.16K

Cash & ST Invst.

$377.00

Total Debt

$6.96M

Endonovo Therapeutics Performance Analysis

Endonovo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 135,35585.2%
20232023-12-31USD 140,2423.6%
20242024-12-31USD 10,043-92.8%
20252025-12-31USD 0N/A
Endonovo Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Endonovo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.13155.7%
20232023-12-31USD 0.01N/A
20242024-12-31USD -0.01N/A
20252025-12-31USD -0.00-76.5%
Endonovo Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$180.80KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$180.80K

N/A

Employees

1

N/A

Net Income

-$586.48K

-10.0%

EBITDA

-$277.13K

-23.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$377.00

+1994.4%

Total Debt

$6.96M

+1.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$6.96M

+1.4%

Return on Assets

-113.38%

N/A

Return on Invested Capital

3.38%

N/A

Free Cash Flow

-$49.63K

-4371.2%

Operating Cash Flow

-$49.63K

-4371.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BSSPBaseline Productions, Inc.
$0.00+0.00%
WIBFFWest Island Brands Inc.
$0.00+0.00%
AFFYAffymax, Inc.
$0.00+0.00%
AMBSAmarantus BioScience Holdings, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About ENDV

What is the current price of Endonovo Therapeutics?

Endonovo Therapeutics is trading at $0.00 per share.

What is the 52-week range for Endonovo Therapeutics?

Over the past 52 weeks, Endonovo Therapeutics has traded between $0.00 and $0.00.

How much debt does Endonovo Therapeutics have?

As of the most recent reporting period, Endonovo Therapeutics reported total debt of $6.96M.

How much cash does Endonovo Therapeutics have on hand?

Endonovo Therapeutics reported $377.00 in cash and cash equivalents in its most recent financial results.

What is Endonovo Therapeutics’s dividend yield?

Endonovo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services